These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Failing the public health--rofecoxib, Merck, and the FDA. Topol EJ N Engl J Med; 2004 Oct; 351(17):1707-9. PubMed ID: 15470193 [No Abstract] [Full Text] [Related]
7. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Couzin J Science; 2004 Oct; 306(5695):384-5. PubMed ID: 15486258 [No Abstract] [Full Text] [Related]
8. COX-2 inhibitor use after Vioxx: careful balance or end of the rope? Fendrick AM Am J Manag Care; 2004 Nov; 10(11 Pt 1):740-1. PubMed ID: 15623263 [No Abstract] [Full Text] [Related]
9. The lessons of Vioxx--drug safety and sales. Waxman HA N Engl J Med; 2005 Jun; 352(25):2576-8. PubMed ID: 15972862 [No Abstract] [Full Text] [Related]
11. Causation, Vioxx, and legal issues. Green MD Science; 2005 Nov; 310(5750):973. PubMed ID: 16284163 [No Abstract] [Full Text] [Related]
12. The Vioxx debacle revisited. Abeles M; Abeles AM Am J Med; 2005 Sep; 118(9):1057-8. PubMed ID: 16164907 [No Abstract] [Full Text] [Related]
13. The law. Vioxx verdict: too little or too much science? Lawler A Science; 2005 Sep; 309(5740):1481. PubMed ID: 16141043 [No Abstract] [Full Text] [Related]
14. How to avoid another 'Vioxx'. Frantz S Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595 [No Abstract] [Full Text] [Related]
15. Lessons learned after the withdrawal of rofecoxib. Giaquinta D Manag Care Interface; 2004 Nov; 17(11):25-6, 46. PubMed ID: 15573801 [No Abstract] [Full Text] [Related]
16. Rofecoxib, Merck, and the FDA. Villalba L; Witter J N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745 [No Abstract] [Full Text] [Related]
17. [Cardiovascular risk: a class effect of coxibs? How to manage patients taking Vioxx?]. Brune K; Zacher J MMW Fortschr Med; 2004 Oct; 146(42):10, 12. PubMed ID: 15536697 [No Abstract] [Full Text] [Related]
18. Health Canada lukewarm on Vioxx panel findings. Murray S CMAJ; 2005 Aug; 173(4):350. PubMed ID: 16103502 [No Abstract] [Full Text] [Related]
19. How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag". Armstrong D Wall St J (East Ed); 2006 May; ():A1, A10. PubMed ID: 16848016 [No Abstract] [Full Text] [Related]